Neuromuscular Manifestations clinical trials at University of California Health
2 in progress, 1 open to eligible people
Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases
open to eligible people ages 18 years and up
The goal of this clinical study is to learn more about the study drug Anitocabtagene autoleucel (anito-cel), and its safety, tolerability, dosing, and preliminary effectiveness in participants with generalized myasthenia gravis (GMG). Anito-cel is a B-cell maturation antigen (BCMA)-directed CAR-T cell therapy. The primary objective of this study is to assess the safety profile, including any dose-limiting toxicity (DLT) and identification of a maximum tolerated dose (MTD) (if applicable), to support selection of the recommended Phase 2 dose (RP2D) of anito-cel when administered to participants with GMG.
at UC Irvine UCLA
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
Sorry, in progress, not accepting new patients
The ONYX study is an Open-Label, Multicenter, Extension study that will evaluate the long-term safety and efficacy of Apitegromab in Patients with Type 2 and Type 3 SMA who have completed TOPAZ or SAPPHIRE.
at UCSD
Our lead scientists for Neuromuscular Manifestations research studies include Ali Habib.
Last updated: